Gurbakhash Kaur, MD

home / authors / gurbakhash-kaur-md

Articles

MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data (Part 2)

Ajai Chari, MD;Ajay Nooka, MD, MPH, FACP;Muhamed Baljevic, MD;Gurbakhash Kaur, MD; Anupama Kumar, MD

June 27th 2025

Panelists discuss how the extended median follow-up data from the MonumenTAL-1 trial demonstrate that Q2 weekly dosing of talquetamab shows superior progression-free survival (11.2 vs 7.5 months), duration of response (19.5 vs 7.5 months), and overall survival compared with weekly dosing, with particularly encouraging efficacy in high-risk cytogenetics and older patients while maintaining a manageable safety profile.

MonumenTAL-1: Outcomes From the Extended Median Follow-Up Data

Ajai Chari, MD;Ajay Nooka, MD, MPH, FACP;Muhamed Baljevic, MD;Gurbakhash Kaur, MD; Anupama Kumar, MD

June 27th 2025

Panelists discuss how bispecific antibodies have evolved in relapsed/refractory myeloma treatment, highlighting recent data developments, the importance of NCCN guideline updates, including prophylactic tocilizumab recommendations, and strategies for improving toxicity management and community practice implementation.